Law firms Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’ Sophie Chan · 9 February 2024 · 3 min read Profile Life Sciences Yearbook 2024 McDermott Will & Schulte David Gibson, senior associate at McDermott Will & EmeryWhy did you decide to specialise in life sciences law, and what’s the best thing about being a life sciences lawyer?Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryTrading Places: Simpson continues K&E raid as Paul Weiss adds disputes in HoustonLaw firmsEliza Winter19 May 2026‘The centre of gravity for Southeast Asia’ – why PE investment is making Singapore increasingly attractiveLaw firmsKate Peacock8 May 2026Revolving Doors: US firms lead hiring as White & Case, Cleary, McDermott build across EuropeLaw firmsEliza Winter8 May 2026M&A perspectives: Melissa FogartyLaw firmsIman Tribak26 Jun 2024M&A perspectives: Jennifer BethlehemLaw firmsIman Tribak26 Jun 2024M&A perspectives: Lorenzo CorteLaw firmsIman Tribak26 Jun 2024Sponsored thought leadership: China life sciences – Transaction insights and notable industry trendsPractice areasGuest Blog9 Feb 2024The Legal 500 view: Healthy competitionLaw firmsBen Wheway9 Feb 2024Life Sciences Yearbook 2024 – Editor’s letterPractice areasGeorgina Stanley9 Feb 2024